| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/16/2003 | EP1075478B1 Phenylurea and phenylthio urea derivatives |
| 04/16/2003 | EP1056449B1 20-hete antagonists and agonists |
| 04/16/2003 | EP1043981B1 Fat-binding polymers combined with lipase inhibitors for the treatment of obesity |
| 04/16/2003 | EP0998451B1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 04/16/2003 | EP0972769B1 Novel amide derivatives and medicinal compositions thereof |
| 04/16/2003 | EP0971913B1 Process for the production of semi synthetic statins via novel intermediates |
| 04/16/2003 | EP0942896B1 Substituted phenols and thiophenols useful as antioxidant agents |
| 04/16/2003 | EP0918455B1 Use of galanin to repair nerve damage |
| 04/16/2003 | CN1411453A Trans olefinic glucokinase activators |
| 04/16/2003 | CN1411447A Polymorphic crystalline forms of celecoxib |
| 04/16/2003 | CN1411446A Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 04/16/2003 | CN1411440A Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 04/16/2003 | CN1410128A Plasmid used directly in intramuscular injection for treating diabetes |
| 04/16/2003 | CN1410125A Medicinal composition containing calcium and iron elements |
| 04/16/2003 | CN1410089A Medicine for treating diabetes, nephropathy |
| 04/16/2003 | CN1410077A Application of fur seal oil in preparation of medicine for treating diabetes |
| 04/16/2003 | CN1410075A Application of fur seal oil in preparation of medicine for treating lipometabolism disorder (high blood fat) |
| 04/16/2003 | CN1410059A Treating method and medicine kit containing somatotrophic hormone secretory agent |
| 04/16/2003 | CN1409999A Method for extracting black-bone chicken extract (natural juice) and black-bone chicken extract obtained thereby |
| 04/16/2003 | CN1105723C Spirocyclic metalloprotease inhibitors |
| 04/16/2003 | CN1105718C Improved method for producing thiazolidinediones, and new thiazolidinediones |
| 04/16/2003 | CN1105577C Parathyroid hormone and raloxifene for increasing bone mass |
| 04/16/2003 | CN1105576C Insulin analog formulation |
| 04/16/2003 | CN1105558C 2,2-dichloroalkane carboxylic acids, process for preparing same, medicament containing same and use for treating insulin resistance |
| 04/16/2003 | CA2407771A1 Mixtures for stimulating glucose up-take |
| 04/15/2003 | US6548739 Method for activating peroxisome proliferator activated receptor-γ |
| 04/15/2003 | US6548687 Chromium L-threonate, process for preparation of the same and their use |
| 04/15/2003 | US6548551 Administration of Citalopram and Phentermine to facilitate weight loss for patient |
| 04/15/2003 | US6548548 Cardiovascular disorders; anticholesterol agents |
| 04/15/2003 | US6548547 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators |
| 04/15/2003 | US6548529 Heterocyclic containing biphenyl aP2 inhibitors and method |
| 04/15/2003 | US6548520 Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| 04/15/2003 | US6548513 (E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methyl -sulfonyl)amino)pyrimidin-5-yl)-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or salt, stabilized by an inorganic salt having a multivalent cation, excluding synthetic hydrotalcite |
| 04/15/2003 | US6548504 Compounds |
| 04/15/2003 | US6548503 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 04/15/2003 | US6548500 Treating a cell adhesion-mediated diseases such as multiple sclerosis, asthma, atherosclerosis, rheumatoid arthritis, meningitis, comprising administering to a warm blooded animal a nitrogen atoms containing bicyclic compound |
| 04/15/2003 | US6548498 Substituted indan derivatives |
| 04/15/2003 | US6548494 3,4-dihydro-2H-(1,4)diazepino(6,7,1-hi)indol-1-one or 1-thione derivatives where indole C3 could also be N; use treating cancers as well as stroke, head trauma, and neurodegenerative diseases |
| 04/15/2003 | US6548493 Substituted heterocycle fused gamma-carbolines |
| 04/15/2003 | US6548489 Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same |
| 04/15/2003 | US6548483 Nutritional preparation comprising ribose and medical use thereof |
| 04/15/2003 | US6548481 A salt form of a dipeptide compound formed from an amino acid and a thiazolidine or pyrrolidine group, and the salts are selected from acetates, tartrates, fumarates, succinates, phosphates and sulfates |
| 04/15/2003 | US6548284 Membrane-bound metalloprotease and soluble secreted form thereof |
| 04/15/2003 | US6548279 For polypeptides able to catalyze the enzymatic function of superoxide dismutase, carbonic anhydrase, or HIV protease |
| 04/15/2003 | CA2047375C Piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis |
| 04/12/2003 | CA2407214A1 Method of monitoring neuroprotective treatment |
| 04/11/2003 | WO2002030872A1 Novel aliphatic compounds, process for their preparation and their usage |
| 04/11/2003 | CA2425923A1 Novel aliphatic compounds, process for their preparation and their usage |
| 04/10/2003 | WO2003029465A1 HepNaDC GENE |
| 04/10/2003 | WO2003029437A2 Secreted proteins |
| 04/10/2003 | WO2003029433A2 Chimeric viral vectors for gene therapy |
| 04/10/2003 | WO2003029424A2 Novel proteins and nucleic acids encoding same |
| 04/10/2003 | WO2003029423A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 04/10/2003 | WO2003029293A2 Modulators of notch ic protease activity for use in immunotherapy |
| 04/10/2003 | WO2003029276A2 Copolymers for suppression of autoimmune diseases, and methods of use |
| 04/10/2003 | WO2003029268A1 Androstane 17-beta-carboxamides as androgen receptor modulators |
| 04/10/2003 | WO2003029247A1 N-heterocyclyl hydrazides as neurotrophic agents |
| 04/10/2003 | WO2003029245A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 04/10/2003 | WO2003029242A1 NF-λB INHIBITORS |
| 04/10/2003 | WO2003029210A2 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 04/10/2003 | WO2003029200A2 Compounds useful as reversible inhibitors of cysteine proteases |
| 04/10/2003 | WO2003029199A1 Benzene derivatives, process for preparing the same and use thereof |
| 04/10/2003 | WO2003028763A1 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 04/10/2003 | WO2003028739A2 Composition for preventing or treating hyperlipidemia or hyperglycemia comprising a polymer or its salt |
| 04/10/2003 | WO2003028736A2 Pharmaceutical preparations comprising alkyl phosphocholine compounds in liposomes which may be sterile-filtered or heat-sterilised |
| 04/10/2003 | WO2003028733A1 Tetracyclic indole derivatives as 5-ht receptor ligands |
| 04/10/2003 | WO2003028732A1 Receptor antagonist |
| 04/10/2003 | WO2003028730A2 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 04/10/2003 | WO2003028727A1 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors |
| 04/10/2003 | WO2003028726A1 Quinoline derivatives as neuropeptide y antagonists |
| 04/10/2003 | WO2003028712A2 Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases |
| 04/10/2003 | WO2003028710A2 Compounds for reducing excessive intake of food |
| 04/10/2003 | WO2003028705A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 04/10/2003 | WO2003028641A2 Mch receptor antagonists |
| 04/10/2003 | WO2003028630A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 04/10/2003 | WO2003028445A1 Tsa2306 knockout non-human animal |
| 04/10/2003 | WO2003028444A1 Nonhuman mammal model of autoimmune disease having ox40l gene transferred thereinto |
| 04/10/2003 | WO2003013563A3 Mineral-protein preparations (mpp) and neuropathies in diabetes |
| 04/10/2003 | WO2003004493A8 Novel compounds, their preparation and use |
| 04/10/2003 | WO2003000178A3 Black soybean polysaccharides |
| 04/10/2003 | WO2002102978A3 Human growth hormone antagonists |
| 04/10/2003 | WO2002102394A3 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
| 04/10/2003 | WO2002094203A3 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 04/10/2003 | WO2002092064A3 Therapeutic method for inducing tolerance |
| 04/10/2003 | WO2002081668A8 Desaturase genes and uses thereof |
| 04/10/2003 | WO2002071827A3 Retinoid x receptor modulators |
| 04/10/2003 | WO2002060423A3 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists |
| 04/10/2003 | WO2002059083A3 Novel compounds |
| 04/10/2003 | WO2002055705A3 Proteins and nucleic acids encoding same |
| 04/10/2003 | WO2002055152A3 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 04/10/2003 | WO2002046406A3 Human transporter proteins, nucleic acid molecules encoding them,and uses thereof |
| 04/10/2003 | WO2002043767A8 Improved oral delivery of peptides using enzyme-cleavable membrane translocators |
| 04/10/2003 | WO2002040666A3 Fat regulated genes, uses thereof, and compounds for modulating same |
| 04/10/2003 | WO2002034241A3 Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents |
| 04/10/2003 | WO2002030440A1 Medicinal compositions for promoting recovery from stress loading and novel matsutake mushroom strain |
| 04/10/2003 | WO2002018321A3 Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors |
| 04/10/2003 | WO2002009678A3 Charged phospholipid compositions and methods for their use |
| 04/10/2003 | WO2002008396A3 Human proteases |
| 04/10/2003 | US20030069430 Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects |
| 04/10/2003 | US20030069429 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |